soul trial oral semaglutide cardiovascular outcomes soul trial results 2024 mace reduction Reduces Events in People with Type 2 Diabetes with Atherosclerotic PDF) Oral Semaglutide and Cardiovascular

The net effect of combining these actions is not well characterised

In Study 5 (NCT#03548987), WEGOVY injection was escalated during a 20-week run-in period, and patients who reached a WEGOVY 2.4 mg subcutaneous injection weekly dosage after the run-in period were randomized to either continued treatment with WEGOVY injection or placebo for 48 weeks

They can help you decide if its the right option based on your needs and goals

This is why semaglutide is increasingly viewed as a long-term or potentially lifelong medication for obesity management, similar to how blood pressure or cholesterol medications are used chronically